MedPath
FDA Approval

Zavesca

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
April 20, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Miglustat(100 mg in 1 1)

Manufacturing Establishments2

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Almac Pharma Services Limited

Actelion Pharmaceuticals US, Inc.

233170864

Lonza AG

Actelion Pharmaceuticals US, Inc.

480007517

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Zavesca

Product Details

NDC Product Code
66215-201
Application Number
NDA021348
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
April 20, 2023
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2Class: IACT
GELATIN, UNSPECIFIEDInactive
Code: 2G86QN327LClass: IACT
POVIDONE K30Inactive
Code: U725QWY32XClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JPClass: IACT
FERROSOFERRIC OXIDEInactive
Code: XM0M87F357Class: IACT
SHELLACInactive
Code: 46N107B71OClass: IACT
MiglustatActive
Code: ADN3S497AZClass: ACTIBQuantity: 100 mg in 1 1
© Copyright 2025. All Rights Reserved by MedPath